Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity

Publisher： Karger

E-ISSN： 1662-8063|17|5-6|248-255

ISSN： 1662-4246

Source： Public Health Genomics, Vol.17, Iss.5-6, 2014-10, pp. : 248-255

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

By Ozeki Takeshi   Mushiroda Taisei   Yowang Amara   Takahashi Atsushi   Kubo Michiaki   Shirakata Yuji   Ikezawa Zenro   Iijima Masafumi   Shiohara Tetsuo   Hashimoto Koji   Kamatani Naoyuki   Nakamura Yusuke  

Human Molecular Genetics, Vol. 20, Iss. 5, 2011-03 ,pp. : 1034-1041

Oxford University Press

Access to resources Recommend Favorite

Pharmacogenomics: Role in Medicines Approval and Clinical Use

By  

Public Health Genomics, Vol. 13, Iss. 5, 2009-10 ,pp. : 284-291

Karger

Access to resources Recommend Favorite

Quantitative proteomics for drug toxicity

By Gao Yuan   Holland Ricky D.   Yu Li-Rong  

Briefings in Functional Genomics and Proteomics, Vol. 8, Iss. 2, 2009-03 ,pp. : 158-166

Oxford University Press

Access to resources Recommend Favorite

ACCE, Pharmacogenomics, and Stopping Clinical Trials: Time to Extend the CONSORT Statement?

By Ozdemir Vural   Joly Yann   Knoppers Bartha  

American Journal of Bioethics, Vol. 11, Iss. 3, 2011-03 ,pp. : 11-13

Routledge Ltd

Access to resources Recommend Favorite

Application of the DruGeVar Database in Cancer Genomics and Pharmacogenomics

By  

Public Health Genomics, Vol. 20, Iss. 2, 2017-07 ,pp. : 142-147

Karger

Access to resources Recommend Favorite